Abstract
Positron emission tomography (PET) using 18F-fluorodeoxyglucose (FDG) is considered to be a very useful adjunct to anatomic imaging techniques and is now primarily used for oncological indications. These indications include diagnosis, staging, and therapy monitoring. In this review, we discuss the articles in which FDG-PET is clinically used for monitoring therapy in lung and colorectal tumours, head and neck cancer, sarcoma, and hepatocellular carcinoma. It is found that the amount of FDG uptake strongly correlates with response to therapy: a decrease in FDG uptake after therapy indicates a positive response to therapy. However, this conclusion is based on small numbers of patients, whereas the exact response mechanism is still unknown. Moreover, in these case series, the interval between tumour therapy and FDG-PET, as well as the method of quantification, SUV or tumour-to-non-tumour ratios, differ per study. Finally, dynamic imaging is a recommended technique by some authors, but it is not a standard technique in clinical practice to evaluate tumour therapy. Therefore, further study is required which has to deal with these major issues before it is possible to draw definite conclusions.
Similar content being viewed by others
Author information
Authors and Affiliations
Additional information
Received: 20 July 2000 / Accepted: 4 September 2000
Rights and permissions
About this article
Cite this article
Stokkel, M., Draisma, A. & Pauwels, E. Positron emission tomography with 2-[18F]-fluoro-2-deoxy-D-glucose in oncology . J Cancer Res Clin Oncol 127, 278–285 (2001). https://doi.org/10.1007/s004320000208
Issue Date:
DOI: https://doi.org/10.1007/s004320000208